Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 19, 2021 10:52am
114 Views
Post# 33569042

RE:RE:RE:Dose escalation

RE:RE:RE:Dose escalation

... or if it's not bypassing resistance so chemo resistant cells are pumping the drug out as fast as Sortilin is moving it in.

.... or if the docetaxel is not efficiently being released from the PDC inside the cell so it doesn't become active.

.... or if the PDC is not able to get to the cells in the first place, that's to say it doesn't efficiently penetrate the tumour.

All the things they highlight about the drug need to work to some extent to get the final effect. Some of these things have been better "derisked" in the preclinical work than others.


jfm1330 wrote: The only explaination would be that docetaxel is not efficacious against certain type of cancers, but it is hard to imagine it would not work against every cancers. That's why the scientific logic leads to think that if the MTD is high, efficacy should be there.

 

stockman75 wrote:
Jfm thanks for this great information/analysis. From a scientific perspective how would you explain a scenario where they have such large MTD dosage and NOT have very good efficacy (for sortllin expressing cancers)? Thanks




<< Previous
Bullboard Posts
Next >>